key: cord-0740110-jqi565vo
authors: Porres-Aguilar, Mateo; Pérez-Nieto, Orlando R.; Zamarrón-López, Éder I.; Ñamendys-Silva, Silvio A.
title: Letter to the Editor: Thromboprophylaxis strategies for COVID-19 patients
date: 2021-07-05
journal: Arch Med Res
DOI: 10.1016/j.arcmed.2021.06.011
sha: 63e4f305e7eebb56d7a8d945b1552fad0adfab6f
doc_id: 740110
cord_uid: jqi565vo

nan

. We believe that detailed and careful screening and selection should be made while deciding to prescribe or not DOACs in post-discharged patients with COVID-19, rather than liberally recommend DOACs. Moreover, more robust prospective randomized data like the double-blind, placebo-controlled, pragmatic, event-driven phase-3 PREVENT-HD trial, which is currently evaluating the efficacy and safety of rivaroxaban in the outpatient setting to reduce thromboembolic events, hospitalization, and mortality associated with COVID-19 (5). Faced with a recent and little-known disease such as COVID-19, we must be cautious when prescribing and instituting thromboprophylaxis strategies, because there may be more risks than benefits in challenging case scenarios, despite a well-established correlation with thromboembolic events in COVID-19 patients, we believe that important scientific pieces of the puzzle are still lacking to draw solid conclusions on what are the best thromboprophylaxis strategies for best clinical practice in this emerging field of thrombosis. We propose an approach for thromboprophylaxis according to the severity of COVID-19 (6,7) (Table 1) .

Finally, we would like to emphasize the potential impact and role of a dedicated, multidisciplinary, team-based approach, VTE response teams, which we believe they play an important part in the care and prevention of VTE in our hospitals; such multidisciplinary teams may individualize, and tailor the best thromboprophylaxis strategy for a given patient, for the best clinical decision making, prioritizing optimal patient care, outcomes, and survival for such devastating disease like VTE (8, 9) . 

An Evidence-based Protocol for Minimizing Thromboembolic Events in SARS-CoV-2 Infection

COVID-19-associated coagulopathy and antithrombotic agents: Lessons after 1 year

Thromboembolic complications in severe COVID-19: Current antithrombotic strategies and future perspectives

Validation of the IMPROVE-DD risk assessment model for venous thromboembolism among hospitalized patients with COVID-19

Rationale and design for the study of rivaroxaban to reduce thrombotic events, hospitalization, and death in outpatients with COVID-19: The PREVENT-HD study

The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. The Epidemiological Characteristics of an Outbreak of 2019 Novel Coronavirus Diseases (COVID-19)-China

Enoxaparin for primary thromboprophylaxis in ambulatory patients with coronavirus disease-2019 (the OVID study): a structured summary of a study protocol for a randomized controlled trial